Total Payments
$2.1M
2024 Payments
$360,947
Companies
60
Transactions
2,514
Medicare Patients
22,799
Medicare Billing
$2.2M
Payment Breakdown by Category
Other$1.6M (77.2%)
Consulting$278,911 (13.3%)
Travel$137,348 (6.6%)
Food & Beverage$60,276 (2.9%)
Education$832.39 (0.0%)
Research$574.60 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 611 | 72.6% |
| Consulting Fee | $278,911 | 120 | 13.3% |
| Travel and Lodging | $137,348 | 334 | 6.6% |
| Honoraria | $65,450 | 26 | 3.1% |
| Food and Beverage | $60,276 | 1,382 | 2.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $16,800 | 8 | 0.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $14,000 | 5 | 0.7% |
| Education | $832.39 | 26 | 0.0% |
| Unspecified | $574.60 | 2 | 0.0% |
Payments by Type
General
$2.1M
2,512 transactions
Research
$574.60
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $276,245 | 382 | $0 (2024) |
| Lilly USA, LLC | $258,394 | 276 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $171,281 | 131 | $0 (2024) |
| UCB, Inc. | $146,874 | 128 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $146,060 | 170 | $0 (2024) |
| Amgen Inc. | $141,979 | 113 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $114,031 | 171 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $92,193 | 86 | $0 (2024) |
| Janssen Biotech, Inc. | $90,145 | 127 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $85,758 | 105 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $360,947 | 415 | UCB, Inc. ($57,054) |
| 2023 | $367,022 | 349 | ABBVIE INC. ($45,275) |
| 2022 | $321,955 | 333 | ABBVIE INC. ($53,857) |
| 2021 | $197,871 | 217 | Amgen Inc. ($50,026) |
| 2020 | $155,633 | 196 | UCB, Inc. ($35,794) |
| 2019 | $213,551 | 331 | Novartis Pharmaceuticals Corporation ($36,810) |
| 2018 | $234,641 | 338 | Lilly USA, LLC ($48,066) |
| 2017 | $243,096 | 335 | Lilly USA, LLC ($76,383) |
All Payment Transactions
2,514 individual payment records from CMS Open Payments — Page 1 of 101
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,940.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $13.51 | General |
| Category: DERMATOLOGY | ||||||
| 12/19/2024 | Eli Lilly and Company | TALTZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Immunology | ||||||
| 12/19/2024 | Eli Lilly and Company | TALTZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Immunology | ||||||
| 12/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.63 | General |
| Category: Immunology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| Category: Immunology | ||||||
| 12/16/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: DERMATOLOGY | ||||||
| 12/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,825.00 | General |
| Category: Immunology | ||||||
| 12/14/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $395.46 | General |
| 12/14/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $135.63 | General |
| 12/14/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $135.63 | General |
| 12/14/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $100.56 | General |
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $5,124.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,562.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $1,281.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $854.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $854.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $427.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $141.66 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $22.91 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,135.00 | General |
| 12/10/2024 | Hikma Pharmaceuticals USA | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $30.71 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $8.07 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $2,550.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Efficacy Safety Study of Apremilast in Subjects With Moderate to Severe Genital Psoriasis (PSOR-025) | Amgen Inc. | $324.60 | 1 |
| PROTOPIC APPLES | LEO Pharma AS | $250.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 5,342 | 11,883 | $1.4M | $492,216 |
| 2022 | 34 | 5,764 | 12,998 | $1.5M | $559,018 |
| 2021 | 35 | 6,008 | 14,269 | $1.6M | $607,208 |
| 2020 | 36 | 5,685 | 13,512 | $1.4M | $505,000 |
Total Patients
22,799
Total Services
52,662
Medicare Billing
$2.2M
Procedure Codes
138
All Medicare Procedures & Services
138 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 1,177 | 2,086 | $312,900 | $137,488 | 43.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 505 | 716 | $143,200 | $65,771 | 45.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 956 | 1,537 | $192,125 | $63,047 | 32.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 629 | 800 | $180,000 | $59,809 | 33.2% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 132 | 205 | $112,750 | $27,297 | 24.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 887 | 5,173 | $181,055 | $26,450 | 14.6% |
| 17263 | Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm | Office | 2023 | 79 | 104 | $31,100 | $14,247 | 45.8% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 169 | 243 | $24,300 | $9,951 | 41.0% |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | Office | 2023 | 22 | 22 | $15,400 | $7,463 | 48.5% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 44 | 48 | $16,800 | $6,714 | 40.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 85 | 85 | $17,000 | $6,617 | 38.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 50 | 50 | $13,750 | $6,338 | 46.1% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 37 | 41 | $16,400 | $6,090 | 37.1% |
| 13101 | Complicated repair of wound of trunk, 2.6-7.5 cm | Office | 2023 | 18 | 18 | $12,600 | $5,588 | 44.4% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 51 | 53 | $10,725 | $5,298 | 49.4% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 21 | 21 | $8,925 | $4,964 | 55.6% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 13 | 16 | $8,800 | $4,907 | 55.8% |
| 17282 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 28 | 31 | $11,625 | $4,770 | 41.0% |
| 17273 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 2.1-3.0 cm | Office | 2023 | 22 | 22 | $9,900 | $3,636 | 36.7% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 28 | 31 | $7,750 | $3,274 | 42.2% |
| 11642 | Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 16 | 16 | $7,200 | $2,899 | 40.3% |
| 69100 | Biopsy of ear | Office | 2023 | 42 | 47 | $9,400 | $2,685 | 28.6% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 61 | 81 | $8,100 | $2,529 | 31.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 26 | 29 | $5,075 | $2,384 | 47.0% |
| 96573 | Application of light by qualified health care professional to destroy precancer skin growth | Office | 2023 | 11 | 14 | $4,550 | $2,359 | 51.9% |
About Dr. Brad Glick, MD
Dr. Brad Glick, MD is a Dermatology healthcare provider based in Margate, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/20/2005. The National Provider Identifier (NPI) number assigned to this provider is 1235134818.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brad Glick, MD has received a total of $2.1M in payments from pharmaceutical and medical device companies, with $360,947 received in 2024. These payments were reported across 2,514 transactions from 60 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.5M).
As a Medicare-enrolled provider, Glick has provided services to 22,799 Medicare beneficiaries, totaling 52,662 services with total Medicare billing of $2.2M. Data is available for 4 years (2020–2023), covering 138 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Margate, FL
- Active Since 06/20/2005
- Last Updated 02/20/2019
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1235134818
Products in Payments
- TALTZ (Drug) $229,713
- Otezla (Drug) $196,923
- TREMFYA (Drug) $172,057
- DUPIXENT (Biological) $142,660
- COSENTYX (Biological) $110,070
- SKYRIZI (Biological) $103,230
- Sotyktu (Drug) $69,129
- SPEVIGO (Drug) $65,990
- Bimzelx (Biological) $65,839
- OPZELURA (Drug) $64,444
- Humira (Biological) $64,108
- RINVOQ (Biological) $55,351
- VTAMA (Drug) $53,526
- EUCRISA (Drug) $41,775
- Tremfya (Drug) $38,863
- Cimzia (Drug) $36,211
- ILUMYA (Biological) $33,902
- DUPIXENT DUPILUMAB INJECTION (Biological) $32,105
- CIBINQO (Drug) $28,587
- STELARA (Biological) $26,303
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.